Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

44.16USD
22 Jun 2017
Change (% chg)

$0.54 (+1.24%)
Prev Close
$43.62
Open
$43.90
Day's High
$44.44
Day's Low
$43.88
Volume
2,781,557
Avg. Vol
3,081,728
52-wk High
$45.58
52-wk Low
$37.20

GSK

Chart for GSK

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $104,526.90
Shares Outstanding(Mil.): 2,458.93
Dividend: 0.49
Yield (%): 4.56

Financials

  GSK Industry Sector
P/E (TTM): 50.36 13.97 18.98
EPS (TTM): 0.87 -- --
ROI: 5.27 -6.80 -5.09
ROE: 74.13 -6.26 -4.32

BRIEF-GSK CEO Walmsley pursuing sale of Maxinutrition brand - Sky News

* Glaxosmithkline Plc CEO Emma Walmsley is pursuing a sale of Maxinutrition, a nutritional products brand - Sky News Source text : http://bit.ly/2s0Hw4u Further company coverage:

3:33pm EDT

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

Jun 21 2017

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

Jun 21 2017

GSK wins $235 million from Teva in Coreg patent trial

June 21 A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

Jun 21 2017

BRIEF-GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​

* ‍GSK and Medicines for Malaria Venture announced positive results from two phase III studies of Tafenoquine​

Jun 12 2017

BRIEF-GSK reports positive results with single-dose tafenoquine in malaria

* GSK and MMV announce positive headline Phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria Further company coverage: (Reporting by UK bureau)

Jun 12 2017

BRIEF-Glaxosmithkline posts FY consol loss

* FY consol net loss EGP 3.9 million versus profit of EGP 69.1 million year ago

Jun 06 2017

BRIEF-Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract

* KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 17 2017

Deals of the day-Mergers and acquisitions

May 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

May 12 2017

Top-10 Glaxo investor Woodford sells out, criticises board

LONDON British fund manager Neil Woodford said on Friday he had sold out of pharma company GlaxoSmithKline after a "frustrating" stint as an investor spanning more than 15 years.

May 12 2017

More From Around the Web

Competitors

Earnings vs. Estimates